glp 1 is a peptide Schematic representation of different GLP-1 analogues previously GLP-1 Receptor Agonist Services for

Description

FDAs concerns with unapproved GLP-1 drugs used for weight loss (2025)

Randomized prospective studies have demonstrated a significant reduction in microvascular and macrovascular complications in patients with T2D when plasma glucose, blood pressure, and plasma lipid concentrations are lowered towards a normal level (315)

Thermal hyperalgesia was assessed by recording the PWL via the Hargreaves radiant heat apparatus (IITC Life Sciences, Woodland Hills, CA)

may escalate to 14 mg based on response Must be taken on an empty stomach with a small sip of water (120 ml) and wait 30 minutes before eating, drinking or taking other oral medicines For semaglutide (Wegovy) used in weight management: Gradual escalation over 1620 weeks, starting at 0.25 mg weekly Target maintenance dose: 2.4 mg once weekly Some patients may remain on 1.7 mg if 2.4 mg is not tolerated For dulaglutide (Trulicity) : Starting dose: 0.75 mg once weekly Can be increased to 1.5 mg, 3 mg, or 4.5 mg weekly depending on response For liraglutide (Victoza) in diabetes: Starting dose: 0.6 mg daily for at least one week Maintenance: 1.2 mg daily, with possible increase to 1.8 mg For liraglutide (Saxenda) in weight management: Gradual weekly increases from 0.6 mg to a target of 3 mg daily All GLP-1 medications follow a dose-escalation protocol to minimise gastrointestinal side effects such as nausea, vomiting, and diarrhoea